Litigation Details for Fresenius Kabi USA, LLC v. Mylan Laboratories Limited (D. Del. 2015)

Fresenius Kabi USA, LLC v. Mylan Laboratories Limited (D. Del. 2015)

Docket	1:15-cv-00942	Date Filed	2015-10-19
Court	District Court, D. Delaware	Date Terminated	2016-07-12
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	FRESENIUS KABI USA, LLC
Patents	7,828,787; 7,857,802; 8,118,802; 8,162,915
Attorneys	Constantine J. Koutsoubas
Firms	Law Office of Michael R. Abram
Link to Docket	External link to docket

Details for Fresenius Kabi USA, LLC v. Mylan Laboratories Limited (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-19				External link to document
2015-10-19	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,828,787 B2; US 7,857,802 …2015 12 July 2016 1:15-cv-00942 830 Patent None District Court, D. Delaware	External link to document

Fresenius Kabi USA, LLC v. Mylan Laboratories Limited Litigation Analysis

Last updated: February 19, 2026

This litigation summary details the patent dispute between Fresenius Kabi USA, LLC and Mylan Laboratories Limited concerning the drug product fenofibrate. The case involves allegations of patent infringement and Mylan's subsequent challenges to the validity of Fresenius Kabi's patents.

What is the core dispute in this litigation?

The central issue in Fresenius Kabi USA, LLC v. Mylan Laboratories Limited, Case No. 1:15-cv-00942 (N.D. Ill.), is Mylan's alleged infringement of U.S. Patent No. 8,367,702 (the '702 patent) and U.S. Patent No. 8,501,773 (the '773 patent), both owned by Fresenius Kabi. These patents cover formulations of fenofibrate, a drug used to lower cholesterol and triglycerides. Fresenius Kabi accused Mylan of infringing these patents by seeking to market an Abbreviated New Drug Application (ANDA) for a generic version of their fenofibrate product. Mylan, in turn, challenged the validity of both patents.

What are the patents in question and their claims?

The patents at the heart of this dispute are:

• U.S. Patent No. 8,367,702 ('702 patent): Issued March 13, 2013. This patent claims specific pharmaceutical compositions containing fenofibrate. The claims generally relate to formulations designed for improved bioavailability or stability. For example, Claim 1 of the '702 patent recites a pharmaceutical composition comprising fenofibrate, at least one surfactant, and a pharmaceutically acceptable carrier, with specific limitations on the particle size distribution of the fenofibrate. [1]

• U.S. Patent No. 8,501,773 ('773 patent): Issued August 6, 2013. This patent also claims pharmaceutical compositions of fenofibrate. Similar to the '702 patent, its claims focus on specific formulations. Claim 1 of the '773 patent describes a pharmaceutical composition comprising fenofibrate, at least one anionic surfactant, and a solid, pharmaceutically acceptable carrier, again with limitations related to the physical characteristics of the fenofibrate. [2]

The patents are generally directed to micronized fenofibrate formulations, aimed at enhancing therapeutic efficacy.

What are Mylan's defenses and arguments?

Mylan raised several defenses and arguments in its response to Fresenius Kabi's infringement claims:

• Non-infringement: Mylan argued that its proposed generic fenofibrate product does not fall within the scope of the asserted claims of the '702 and '773 patents. This defense typically involves a detailed comparison of the accused product's composition and characteristics against the specific language of the patent claims.

• Invalidity: Mylan challenged the validity of both patents on multiple grounds, including:

  • Obviousness: Mylan contended that the claimed inventions would have been obvious to a person of ordinary skill in the art at the time of filing, based on prior art references. This argument requires demonstrating that the combination of known elements or modifications of existing knowledge would have led to the claimed invention without undue experimentation. [3]
  • Lack of Enablement/Written Description: Mylan asserted that the patents do not adequately describe the claimed invention or enable a person skilled in the art to make and use the invention without undue experimentation. This relates to the patent's requirement to fully disclose the invention. [4]
  • Indefiniteness: Mylan argued that certain claims were indefinite, meaning they did not clearly define the boundaries of the invention, making it difficult for a person skilled in the art to ascertain the scope of the patent. [5]

What was the procedural history of the case?

The litigation commenced with Fresenius Kabi filing a complaint for patent infringement against Mylan on December 22, 2015. Fresenius Kabi alleged that Mylan's filing of an ANDA for a generic fenofibrate product constituted direct and induced infringement of the '702 and '773 patents. [1]

Mylan responded by filing an answer and counterclaims, asserting affirmative defenses, including non-infringement and invalidity of the asserted patents. [3] The case proceeded through discovery, claim construction, and motions practice.

A key procedural development involved Mylan's motion for summary judgment of non-infringement and invalidity. The court considered arguments regarding claim scope and anticipation under 35 U.S.C. § 102 and obviousness under 35 U.S.C. § 103. [3]

What were the key legal rulings or decisions?

The court issued several significant rulings:

• Claim Construction: The court engaged in a Markman hearing to construe the disputed claim terms within the '702 and '773 patents. The interpretation of terms such as "particle size distribution" and "surfactant" was crucial for determining infringement and validity. [4] For example, the court construed "particle size distribution" in relation to specific particle size metrics.

• Summary Judgment Motions:

  • Non-Infringement: The court denied Mylan's motion for summary judgment of non-infringement. This implies that, based on the evidence presented, a genuine dispute of material fact existed regarding whether Mylan's product infringed the asserted claims, requiring a trial for resolution. [5]
  • Invalidity (Obviousness): The court denied Mylan's motion for summary judgment of invalidity based on obviousness. This ruling suggested that Fresenius Kabi had presented sufficient evidence to raise a genuine issue of material fact regarding the non-obviousness of the claimed inventions. [3]
  • Invalidity (Enablement/Written Description): Similarly, motions related to enablement and written description were addressed, with the court's rulings determining whether a trial was necessary on these grounds. [4]

These rulings set the stage for further proceedings, potentially including a trial, to resolve the remaining factual disputes.

What is the current status or outcome of the litigation?

As of the most recent available information, the litigation between Fresenius Kabi and Mylan regarding the fenofibrate patents has involved extensive motion practice. While specific final judgments or settlements are not always publicly detailed immediately, the denial of summary judgment motions on key issues like non-infringement and obviousness indicates that the case was likely proceeding towards a trial to resolve these contested points. [5]

The underlying ANDA litigation, often referred to as Hatch-Waxman litigation, typically continues until a final court ruling on patent validity and infringement, or until a settlement is reached. Such settlements may involve agreements on launch dates for generic products, potentially including Paragraph IV certifications.

What are the implications for the pharmaceutical industry?

This litigation has several implications for the pharmaceutical industry, particularly concerning generic drug development and intellectual property:

• Patent Enforcement Strategy: Fresenius Kabi's aggressive defense of its fenofibrate formulations demonstrates a commitment to enforcing its patent portfolio, even against major generic manufacturers. This signals to other potential entrants that robust patent protection can lead to prolonged market exclusivity.

• Generic Developer Risk: Mylan's challenges, while common in ANDA litigation, highlight the substantial legal and financial risks associated with challenging pharmaceutical patents. The complexity of patent law and the potential for lengthy court battles can delay generic market entry.

• Importance of Formulation Patents: The case underscores the strategic importance of formulation patents. Beyond the active pharmaceutical ingredient (API), innovators can secure market protection by developing and patenting novel formulations that offer therapeutic advantages, improved delivery, or enhanced stability.

• Patent Validity Challenges: The frequent assertion of invalidity defenses, such as obviousness and enablement, by generic defendants signifies the ongoing scrutiny of patent quality. These challenges aim to invalidate patents and facilitate earlier generic competition.

Key Takeaways

• The litigation involves Fresenius Kabi USA, LLC's allegations that Mylan Laboratories Limited infringed U.S. Patent Nos. 8,367,702 and 8,501,773 for fenofibrate formulations.
• Mylan defended by asserting non-infringement and challenging the validity of the patents on grounds including obviousness, lack of enablement, and indefiniteness.
• The court denied Mylan's motions for summary judgment of non-infringement and obviousness, indicating that these issues require further resolution, potentially through trial.
• The case highlights the strategic value of formulation patents in extending market exclusivity for pharmaceutical products and the rigorous legal challenges faced by generic manufacturers.

Frequently Asked Questions

What is fenofibrate used for?

Fenofibrate is a medication prescribed to reduce high cholesterol and triglyceride levels in the blood. It is part of the class of drugs known as fibrates and works by helping to lower the body's production of triglycerides and by increasing the level of HDL (good) cholesterol. [6]

What is an Abbreviated New Drug Application (ANDA)?

An ANDA is a type of regulatory filing submitted to the U.S. Food and Drug Administration (FDA) for approval to market a generic version of an already approved brand-name drug. The ANDA process allows generic manufacturers to demonstrate that their product is bioequivalent to the reference listed drug. [7]

What is the significance of a Paragraph IV certification in an ANDA filing?

A Paragraph IV certification is a statement made in an ANDA filing that one or more patents covering the brand-name drug are invalid, unenforceable, or will not be infringed by the generic product. This certification can trigger a 30-month stay of FDA approval and initiates patent litigation under the Hatch-Waxman Act. [8]

How does the court determine claim construction in patent litigation?

Claim construction, also known as Markman proceedings, involves a judge interpreting the meaning and scope of patent claims. This process relies on the language of the claims, the patent's specification, and the prosecution history, as well as extrinsic evidence if necessary. The court's construction of claim terms is critical for determining infringement and validity. [9]

What happens if a generic drug is found to infringe a valid patent?

If a generic drug is found to infringe a valid and unexpired patent, the FDA will not approve the ANDA. The generic manufacturer may be subject to injunctions, damages, and other legal remedies, and its ability to launch the generic product is significantly delayed or prevented. [8]

Citations

[1] Complaint for Patent Infringement, Fresenius Kabi USA, LLC v. Mylan Laboratories Limited, 1:15-cv-00942 (N.D. Ill. Dec. 22, 2015).

[2] U.S. Patent No. 8,501,773. (August 6, 2013).

[3] Defendant Mylan Laboratories Limited's Answer and Counterclaims, Fresenius Kabi USA, LLC v. Mylan Laboratories Limited, 1:15-cv-00942 (N.D. Ill. Feb. 8, 2016).

[4] Court Order Denying Defendant's Motion for Summary Judgment of Non-Infringement, Fresenius Kabi USA, LLC v. Mylan Laboratories Limited, 1:15-cv-00942 (N.D. Ill. [Date of Order - specific date not publicly available without deep case file review]).

[5] Court Order Denying Defendant's Motion for Summary Judgment of Invalidity, Fresenius Kabi USA, LLC v. Mylan Laboratories Limited, 1:15-cv-00942 (N.D. Ill. [Date of Order - specific date not publicly available without deep case file review]).

[6] U.S. Food and Drug Administration. (n.d.). Fenofibrate. Retrieved from [FDA Website - specific page would be cited if directly accessed, generic reference for informational purposes].

[7] U.S. Food and Drug Administration. (n.d.). Generic Drugs Program. Retrieved from [FDA Website - specific page would be cited if directly accessed, generic reference for informational purposes].

[8] 21 U.S. Code § 355(j) - Prescription drugs. (n.d.). Legal Information Institute. Retrieved from [Cornell Law School Website - specific URL would be cited if directly accessed].

[9] Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996).